Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

A 75-year-old man with non-small cell lung cancer shows radiologic enlargement after neoadjuvant therapy; however, ...

Because treatment is highly individualized, the involvement of team members may vary. A typical gastric cancer team could ...

mRNA vaccines can enhance immunotherapy efficacy by activating the immune system, improving outcomes in hard-to-treat tumors. mRNA COVID-19 vaccines enhance immune responses, improving cancer ...

Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of ...

Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.

In a Nov. 21 note, he maintained a “Speculative Buy” rating and C$5.25 (US$4.00) target.

New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation ...